Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmonary-Allergy Drugs Advisory Committee

Executive Summary

Committee will meet April 20 to review Astra USA's Pulmicort Respules (budesonide nebulizing suspension, NDA 20-929) for maintenance and treatment of asthma and for the prophylactic treatment of asthma in children six to eight years old and in children six months to eight years old who require systemic corticosteroid administration where adding Pulmicort Respules may reduce or eliminate need for corticosteroids. The meeting will begin at 8 a.m. at the Hilton in Gaithersburg, Md...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel